The reversible O-linked attachment of single β-D-N-acetylglucosamine (GlcNAc) moieties to serine/threonine residues in target proteins is a frequently occurring post-translational modification affecting the functionality of many cellular systems. In this report we present experimental evidences suggesting that the epidermal growth factor receptor (EGFR) is subjected to O-GlcNAcylation in human carcinoma epidermoid A431 and human lung carcinoma A549 cells.
Introduction
Protein O-GlcNAcylation is a post-translational modification first identified in lymphocyte proteins 1 , consisting in the reversible O-linked attachment of single β-D-N-acetylglucosamine (GlcNAc) moieties to serine/threonine residues in target proteins; thus modifying their enzymatic activity, intracellular location, turnover, and/or other functional roles 2 . Since those early days, literally hundreds of additional cytosolic, nuclear and mitochondrial proteins have been identified to be O-GlcNAcylated, and it is likely that this number would be growing in the future. Altered O-GlcNAcylation has been proposed to contribute to the etiology of many illnesses such type-2 diabetes [3] [4] [5] [6] , cardiovascular ailments 3, 7 , neurodegeneration as in Alzheimer's disease 3, 4, 8, 9 and cancer 4, 10-
.
The enzymes O-linked β-N-acetylglucosamine transferase (OGT) 14 and
O-linked β-N-acetylglucosaminidase (OGA) 15 catalyze the reversible OGlcNAcylation of proteins, the first one doing the glycosylation and the latter one the deglycosylation. Several OGT isoforms are present in the cell, more relevantly a canonical long form localized in the nucleus and cytosol (ncOGT),
another one a bit shorter localized in the inner mitochondrial membrane (mOGT), and a third one, the shortest of them (sOGT), also localized in the nucleus and cytosol 14 . In addition, an atypical epidermal growth factor (EGF)-like-repeat domain specific OGT (EOGT) able to O-GlcNAcylate the side chain of Ser/Thr at the extracellular segment of different proteins, including Dumpy in Drosophila and the Notch receptor in mouse, has been identified [16] [17] [18] .
Protein O-GlcNAcylation appears to be at the same footing than protein phosphorylation in terms of importance in regulating signal transduction events;
and indeed it exists a complex crosstalk between both events taking place either at the same site, or at distinct adjacent, proximal or distant sites, competing or facilitating each other in the choreographic orchestration of signaling fluxes regulating multiple pathways implicated in the physiology of the cell, such as: metabolic control, stress response, epigenetic modification, gene transcription, translation of proteins, protein turnover, differentiation, apoptosis and cell cycle control to mention a few 4, [19] [20] [21] [22] . Moreover, O-GlcNAcylation of some proteins can also affect its phosphorylation at tyrosine residues, as it is the case of prohibitin 23 .
Among the OGT substrates a large set of serine/threonine-and tyrosinekinases were identified, amounting to forty-two of a total of 152 candidate kinases tested in a particular study 24 . Moreover, and of interest to the present study, the insulin receptor, a relevant member of the receptor tyrosine kinase (RTK) superfamily, is also subjected to O-GlcNAcylation, process that modulates the functionality of the receptor and down-stream signaling pathways 25 . However, little information is available on O-GlcNAcylation of other RTKs.
The epidermal growth factor receptor (EGFR) is an RTK implicated in the control of cell proliferation, differentiation, cell survival, programmed cell death and cell migration processes, and this receptor is frequently overexpressed or mutated in many solid tumors thus contributing to cancerogenesis 26, 27 . In an early report, using high throughput proteomic analysis, labeling proteins of Drosophila melanogaster with the GlcNAc analogue azido-GlcNAc, the EGFR type III was identified, suggesting that it was susceptible to undergo O-
GlcNAcylation
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. Thereafter, in an entirely in silico study it was proposed that the human EGFR could be subjected to O-GlcNAcylation at Thr654 and Ser1046/Ser1047 29 , phosphorylation sites of protein kinase C (PKC) 30 and calmodulin-dependent protein kinase II (CaMK-II) 31 , respectively. However, experimental evidence for this proposed post-translational modification of human EGFR is lacking up to day. In this report we shall provide for the first time proof that indeed the human EGFR could be subjected to O-GlcNAcylation in two distinct tumor cell lines, discuss the uncertainties pending to be resolved on the occurrence of this post-translational modification in the EGFR, and suggest potential physiological consequence of this event for the functionality of the receptor. 
Material and Methods
Reagents and antibodies
Benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BADGP), O-(2- acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenyl carbamate (PUGNAc), 3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol (Thiamet G),
EGFR and OGT co-immunoprecipitation
Co-immunoprecipitation of EGFR and OGT from A431 cells (2 mg protein) was performed using the Pierce TM Classic Magnetic IP/Co-IP kit and either anti-EGFR or anti-OGT antibodies following the manufacture instructions.
The samples were processed for SDS-PAGE and Western blot using both anti-EGFR and anti-OGT antibodies to detect co-immunoprecipitation of the two proteins.
In vitro EGFR O-GlcNAcylation
Immunoprecipitated EGFR was used as substrate for in vitro O- 
N-deglycosylation of the EGFR
The immunoprecipitated EGFR was first denatured in a buffer containing 0.5 % (w/v) SDS and 40 mM dithiothreitol and boiled for 10 min at 100 °C. Higher concentrations of tunicamycin to attain more N-deglycosylated EGFR molecules was not possible as more drastic treatments result in extensive cell death. 
Effect of OGT and OGA inhibitors on EGFR O-GlcNAcylation in living cells
Statistical analysis
The two-tailed paired Student's t test was performed using the Microsoft Excel (Microsoft Co., Redmon, WA) software program. Data were expressed as the mean ± SEM and differences were considered significant at p ≤ 0.05.
Results
Protein O-GlcNAcylation in A431 tumor cells
We first tested for the presence of O-GlcNAcylated proteins in whole cell lysates of A431 tumor cells by Western using two distinct (CTD110.6 and RL2)
anti-O-GlcNAc specific antibodies (Fig. 1A) . The presence of multiple strongly labeled bands of O-GlcNAcylated proteins in a range of > 250 kDa to < 50 kDa were detected presenting a similar distribution pattern when both antibodies were used. Fainter bands were also detected in overexposed films (not shown).
When cells were treated with Thiamet G, a highly specific OGA inhibitor to prevent O-GlcNAc deglycosylation 33 , a significant two-fold increase in protein O-GlcNAcylation level was detected as expected (Figs. 1B-1D) . Moreover, we also tested BADGP, a general O-glycosylation inhibitor not specific for OGlcNAcylation but that also inhibits this process [34] [35] [36] [37] , and a small but significant decrease in protein O-GlcNAcylation was detected (Figs. 1B, 1C ).
EGFR O-GlcNAcylation detected by immunoblots
To determine whether the EGFR from A431 tumor cells undergoes O- (Fig. 2C) .
Furthermore, we performed the experiment in reverse,
immunoprecipitating first O-GlcNAcylated proteins from an A431 cell lysate and detecting the presence of EGFR in the immunoprecipitate (Fig. 2D) . When the cells were previously treated with the OGA inhibitor Thiamet G, the EGFR signal was slightly increased, although not significant decrease was detected when cells were treated with the O-glycosylation inhibitor BADGP (Fig. 2D ). In agreement with this, we also demonstrated that when A431 cells were treated with Thiamet G the O-GlcNAcylation level of the immunoprecipitated native 170 kDa EGFR also increased, although little if any increment was detected in the ~150 kDa N-glycans-free EGFR band (Figs. 3A, 3B ).
EGFR O-GlcNAcylation detected by metabolic labeling with azido-GlcNAc
We next tried to detect O-GlcNAcylation of the EGFR by metabolically labeling cellular glycans in proteins from A431 cells with azido-GlcNAc. Fig. 4A shows that after immunoprecipitation both the native 170 kDa EGFR and its , and we further document this degradation in Figs. 4B, 4C.
We also treated A431 cells with tunicamycin to obtain EGFR devoid of Nglycans by a different method. Fig. 4D shows that the native 170 kDa receptor and its ~150 kDa N-deglycosylated form both were metabolically labeled with azido-GlcNAc, even after further treating the immunoprecipitate EGFR with PNGase F.
EGFR O-GlcNAcylation in different cell lines
We tested different human tumor cell lines, with distinct levels of EGFR expression, and a mouse fibroblast stably transfected and overexpressing the human EGFR for O-GlcNAcylation of the receptor. 
GlcNAcylation of the EGFR was detected in human cervix adenocarcinoma
HeLa cells or in the recombinant human EGFR ectopically expressed in mouse EGFR-T17 fibroblasts.
In vitro EGFR O-GlcNAcylation
To attain a further proof that the EGFR could be O-GlcNAcylated, we assayed in vitro the enzymatic activity of immunoprecipitated OGT from A431 cells using as substrate the immunoprecipitated EGFR from the same origin.
We first show that EGFR and OGT can be co-immunoprecipitated (Fig. 6A) 
Discussion
Overall our results show for the first time that human EGFR could be subjected to O-GlcNAcylation, as it is the case for the insulin receptor Alternatively, the increased immunoreactivity of the anti-O-GlcNAc antibodies after the removal of the N-glycans by PNGase F, could be also related to the extracellular O-GlcNAcylation of the receptor, modification driven by EOGT [16] [17] [18] .
We identified in the extracellular region of the EGFR three sites 41 . These sites are in the S1 and S2 cysteine-rich regions of the receptor, and the cysteine residues located in the proposed sequences are involved in the formation of disulfide bridges 42 . Moreover, the strict specificity of some of the anti-O-GlcNAc antibodies has been questioned, as for example the CTD110.6 antibody that also recognizes terminal β-GlcNac in complex N-glycans 43 .
PNGase F is extensively used to remove N-glycans from glycoproteins 44 , but this endoglycosidase is unable to work if a α1-3 bond links fucose to the innermost GlcNAc attached to asparagine 45 . Although α1-3-linked fucose to the innermost GlcNAc residues attached to asparagine is common in plant and insect glycoproteins, it appears to be absent in mammalian cells, where α1-6-linked fucosylation of core GlcNAc catalyzed by fucosyl transferase 8 (FUT8) appears to be the norm 46 . Nevertheless, to eliminate the possible existence of an unrecognized aberrant α1-3-linked fucosylation of the innermost GlcNAc attached to asparagine in tumor cells we used tunicamycin treatment. Our results with tunicamycin also supports absence of α1-3-linked fucosylation of core GlcNAc in the EGFR from A431 cells, as GlcNAz labeling was clearly detected in the ~150 kDa N-deglycosylated EGFR.
The suggestion that the EGFR could be subjected to O-GlcNAcylation at Thr654 and Ser1046/Ser1047 based on in silico modeling as proposed by
Kaleem et al. 29 is pending experimental confirmation, as many predicting software programs are prone to both false-positive and false-negative predictions 47 . We attempted some experiments using mass spectrometry (MS) We have demonstrated that phosphorylation of Thr654 by PKC prevents CaM binding to this region, and conversely binding of CaM prevents Thr654 phosphorylation by PKC 48 . Thus, it is expected that if Thr654 were targeted by OGT a more complex functional picture could emerge by the presence of this O-GlcNAcylated residue. Particularly, since phosphorylation of Thr654 appears to inhibit ligand-dependent EGFR activation and maintaining the receptor in stand-by at the plasma membrane slowing its internalization 49 , and CaM binding appears to contribute to ligand-dependent EGFR activation in living cells 50 .
Finally, another important issue to be studied in future work would be to establish the potential impact that O-GlcNAcylation may have on EGFR functionality, particularly its putative action on ligand-dependent activation, receptor downregulation, membrane location, nuclear translocation, internalization, intracellular traffic and/or degradation via the lysosomal and/or the ubiquitin-proteasome pathways. Interestingly, it is known that the EGFR can be located in non-caveloar lipid rafts 51 , as also occurs with a fraction of the OGlcNAc transferase when cells are stimulated with insulin 52 . This suggests that the co-localization of OGT and the EGFR at the same membrane microdomains could facilitate the O-GlcNAcylation of the receptor. How these events may affect important EGFR-mediated cellular functions, such as cell proliferation, differentiation, cell survival, programmed cell death and/or cell migration processes warrant also special attention, as well as how this posttranslational modification of the EGFR may goes awry in pathological conditions such as cancer.
Conclusion
We conclude that the accumulated experimental evidences presented in this report using different techniques strongly suggest that the human EGFR 
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